Caribou Biosciences Inc. (CRBU) has reported recent financial results and provided updates on its clinical programs, with key data disclosures anticipated in the coming months.

**Financial Performance:**

*   Caribou Biosciences reported its second-quarter 2025 financial results on August 12, 2025. The company announced revenues of $2.67 million, surpassing consensus estimates, and a reported earnings per share (EPS) of ($0.35), which also topped estimates.
*   As of June 30, 2025, Caribou held $183.9 million in cash, cash equivalents, and marketable securities, which is projected to fund its current operating plan into the second half of 2027.
*   For the fourth quarter and full year 2024, the company reported financial results on March 10, 2025. At the end of 2024, Caribou had $249.4 million in cash and equivalents, expected to support operations into the second half of 2026. Fourth-quarter 2024 revenue was $2.1 million, and full-year 2024 revenue reached $10.0 million. The net loss for Q4 2024 was $35.5 million, with a full-year 2024 net loss of $149.1 million.

**Clinical Pipeline Updates:**

*   **CB-010:** This clinical-stage allogeneic anti-CD19 CAR-T cell therapy is being developed for B cell non-Hodgkin lymphoma (B-NHL) and lupus nephritis (LN) and extrarenal lupus (ERL). Caribou completed enrollment of a 20-patient confirmatory cohort for its ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). The company continues to observe encouraging signs that a single dose of CB-010 can achieve outcomes comparable to approved autologous CAR-T cell therapies. Data from this trial is expected to be disclosed in the second half of 2025, and Caribou is engaging with the FDA regarding a potential pivotal trial. The GALLOP Phase 1 trial for CB-010 in lupus was initiated in January 2025.
*   **CB-011:** An allogeneic anti-BCMA CAR-T cell therapy, CB-011 is being evaluated for relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage Phase 1 clinical trial. Caribou has completed planned enrollment for the dose escalation portion of this trial, with dose levels 1 through 4 clearing without dose-limiting toxicities. The company continues to observe encouraging efficacy in patients treated with CB-011 at active dose levels, particularly following a deeper lymphodepletion regimen. Dose escalation data from the CaMMouflage trial is also anticipated in the second half of 2025.
*   **Pipeline Prioritization:** On April 24, 2025, Caribou Biosciences announced a strategic pipeline prioritization, focusing on its CB-010 and CB-011 oncology programs.

**Upcoming Events and Recent Developments:**

*   Caribou is scheduled to report its third-quarter 2025 earnings on November 5, 2025, with a conference call set for November 7, 2025.
*   The company participated in the Citi 2025 Biopharma Back to School Conference on August 25, 2025.
*   In the first quarter of 2025, Caribou Biosciences reduced its workforce by approximately 32%.
*   Analyst sentiment for CRBU is currently mixed, although institutional ownership remains high, exceeding 77%.